STOCK TITAN

Dr. Reddy`s Laboratories Ltd. - RDY STOCK NEWS

Welcome to our dedicated news page for Dr. Reddy`s Laboratories Ltd. (Ticker: RDY), a resource for investors and traders seeking the latest updates and insights on Dr. Reddy`s Laboratories Ltd..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Dr. Reddy`s Laboratories Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Dr. Reddy`s Laboratories Ltd.'s position in the market.

Rhea-AI Summary
Dr. Reddy's tocilizumab biosimilar candidate, DRL_TC, successfully met its primary and secondary endpoints in a Phase I study. The study demonstrated pharmacokinetic equivalence, safety, and immunogenicity compared to reference products. Dr. Reddy's is now initiating a global Phase III study to compare efficacy, safety, tolerability, and immunogenicity with the reference product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
clinical trial
-
Rhea-AI Summary
Dr. Reddy’s Laboratories announced its financial results for Q4 and FY23. Q4 revenue was up 16% YoY and down 7% QoQ. Gross margin was 57.2%. EBITDA was 25.9% of revenues, up 26% YoY and down 17% QoQ. Profit before tax was up 434% YoY and down 19% QoQ. Profit after tax was up 996% YoY and down 23% QoQ.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.01%
Tags
earnings
-
Rhea-AI Summary
Coya Therapeutics announces positive clinical data for COYA 302 in ALS patients and upcoming presentation on COYA 301 in Alzheimer's Disease. The company also appoints new Chief Business Officer and enters into licensing agreements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.9%
Tags
earnings
Rhea-AI Summary
Coya Therapeutics announces positive clinical data for COYA 302 in ALS patients and upcoming presentation on COYA 301 in Alzheimer's Disease. The company also appoints new Chief Business Officer and enters into licensing agreements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.01%
Tags
earnings
-
Rhea-AI Summary
Dr. Reddy's Laboratories launches generic version of Regadenoson Injection in the U.S. market
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.26%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.31%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.55%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
earnings
Dr. Reddy`s Laboratories Ltd.

NYSE:RDY

RDY Rankings

RDY Stock Data

12.26B
119.82M
14.98%
0.43%
Medicinal and Botanical Manufacturing
Manufacturing
Link
India
Hyderabad

About RDY

They are an Indian multinational pharmaceutical company located in Hyderabad, Telangana, India. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited.